
|Articles|April 26, 2016
Disease Interception and the US National Cancer Moonshot
Author(s)DIA
April 26, 2016.
Advertisement
In the US, patients, caregivers and advocates, drug developers and the FDA have moved towards a patient-centered approach to drug development. The National Cancer Moonshot, a task force led by Vice President Joseph Biden, includes this patient-centric strategy in its agenda: Seeking to facilitate collaborations with researchers, doctors, philanthropies, patients, patient advocates, and biotechnology and pharmaceutical companies to accelerate the early detection and treatment of cancer, its goal is a decade’s worth of advances in five years.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive
2
U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
Navigating PBM Pitfalls: Protecting Revenue in a Complex Rebate Landscape
5




